Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biosynthetic anthracyclines

F Arcamone1, G Cassinelli

  • 1Menarini Ricerche, Via Tito Speri, 10, 00040 Pomezia (Rome) and C.N. R.-I.Co.C.E.A. Via P. Gobetti 101, 40129, Bologna, Italy. federico.maria.arcamone@galactica.it

Current Medicinal Chemistry
|October 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantum mechanics: why complex Hilbert space?

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2017
Same author

Studies on the chemistry of a glucoside a antibiotic from a Streptomyces sp.

Antibiotics & chemotherapy (Northfield, Ill.)·2014
Same author

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Biochemical pharmacology·2013
Same author

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.

Molecular carcinogenesis·2008
Same author

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.

British journal of cancer·2004
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
See all related articles

Biosynthetic anthracyclines, natural products from Streptomyces, are vital in cancer treatment. Further research is needed to fully evaluate their antitumor potential due to limited comparative data.

Area of Science:

  • Natural Products Chemistry
  • Microbiology
  • Pharmacology

Background:

  • Biosynthetic anthracyclines are natural products from Streptomyces species.
  • They are glycosides with a tetracyclic aglycone and deoxysugar units.
  • This class includes clinically significant anticancer agents.

Purpose of the Study:

  • To review the structure, occurrence, and bioactivity of biosynthetic anthracyclines.
  • To assess the current data on structure-activity relationships.
  • To identify gaps in pharmacological knowledge.

Main Methods:

  • Literature review of biosynthetic anthracyclines.
  • Analysis of structural and biosynthetic data.
  • Evaluation of available bioactivity information.

Related Experiment Videos

Main Results:

  • Anthracyclines share a common biosynthetic pathway.
  • Structural data and some structure-activity relationships are known.
  • Published data are insufficient for comparative efficacy evaluation.

Conclusions:

  • Biosynthetic anthracyclines are a promising class of natural products for cancer therapy.
  • Further pharmacological investigation is required.
  • The field remains open for exploring their full therapeutic potential.